Abstract:Objective ：This study aims to analyze the clinical features, prognostic characteristics and gene mutations of the primary myelodysplastic syndrome with myelofibrosis (MDS-MF) patients, ultimately to improve the cognition of MDS-MF. Methods ：From January 1, 2013 to February 1, 2020, 417 newly diagnosed primary MDS patients in the first affiliated hospital of Zhejiang University with bone marrow (BM) biopsy examination were included. They were divided into two groups according to whether BM associated with fibrosis (2005 European Myelofibrosis Network criteria), the MDS-MF group(MF grades 1-3）and the MDS without MF group (MDS-MF0).The clinical features, prognosis characteristics and gene alterations were analyzed between the two groups retrospectively. Results ： ① MF was confirmed in 46.3％（193/417）cases of all the MDS patients, of which 66.3％（128/193）were MF-1 , 25.9％（50/193）were MF-2 and 7.8%(15/193) were MF-3 respectively. The proportion of MDS-EB in MDS-MF group was 48.2%(93/193) and significantly higher than in MDS-MF0 group 35.7%（80/224）,the difference had statistical significance(P=0.008). However, the occurrence of MF does not differ among the MDS subtypes according to the 2016 WHO classification (P=0.342). ② The clinical features of the two groups had statistically significant differences in the higher number of BM blast cells(P=0.006), higher prevalence of death (P=0.031), higher rate of Leukemic transformation (P<0.001), higher level of serum lactate dehydrogenase (LDH) in the peripheral blood (p<0.001), higher level of β2-microgram in the peripheral blood(p=0.003) and higher level of C-reactive Protein (CRP) in the peripheral blood (P=0.004) in the MDS-MF group than in the MDS-MF0 group. The number of WBC, Hb, PLT and Ferritin at the first diagnosed in our hospital were no difference compared the two groups (All P>0.05). The sex, Age and the IPSS-R score(IPSS-R >3.5 v ≤3.5) were no difference in the two groups (ALL P>0.05). ③Compared with MDS-MF0 group, MDS-MF were significantly associated with worse OS(P=0.035) and worse PFS(p<0.001). The median overall survival was 13.20(0.07-90.70) months in MDS-MF group, and was 23.77(0.53-98.97) months in MDS-MF0 group respectively. Subgroup analysis showed that both OS and PFS of either the MDS-MF1-2 group or the MDS-MF 3 group were also significantly worse than those of the MDS-MF0 group（P＝0.013 and <0.001 respectively）. ④Among all the patients ,337 were finished Next-generation-sequencing (NGS) test, sequencing errors and all known or possible single-nucleotide polymorphisms were excluded. The number of mutations (>2) was more frequently in the MDS-MF, the difference had statical significance(P=0.030). The RNA splicing was more frequently in the MDS-MF than the MDS without MF, the difference also had statical difference(P=0.025). The ratio of U2AF1 mutation occurred in MDS-MF group higher than MDS-MF0 group, the difference had statical significance (P=0.027). There was totally 14.2% (48/337) patients with the mutation of U2AF1, of which 19.7%（29/147) in MDS-MF group and 10.0%（19/190) in MDS-MF0 group. Conclusion: MDS-MF has unique laboratory and clinical characteristics. MF is an independent risk factor for shorter overall survival (OS) and worse progression-free survival (PFS) in primary MDS. Evaluation of MF is very significant for prognosis judgment in primary MDS. The U2AF1 mutation may be a biomarker related to the occurrence and poor prognosis of MDS-MF. However, the mechanism of U2AF1 in MDS-MF patient needs to be further explored. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Expression of Fas(CD95) and Fas Ligand in the Marrow of Patients with Myelodysplastic Syndromes and Their Effects on Progenitor Cells

Increased Fatty Acid Synthase As a Potential Therapeutic Target in Multiple Myeloma

Considering Fas ligand as a target for therapy.

Study on Proliferation Inhibiting and Apoptosis Inducing Effects of Cerulenin on Multiple Myeloma Cells

Increased Fatty Acid Synthase is a Therapeutic Target in Multiple Myeloma.

Measurement of Apoptosis and Tumor Necrosis Factor-Α(tnfα) in the Marrow of Patients with Mvelodvsplastic Svn Dromes

Fas/FasL and Bronchial Asthma

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Ambivalent role of FasL in murine acute graft-versus-host-disease

Clinical significance of apoptosis of bone marrow cells in patients with myelodysplastic syndromes

Enhanced Apoptosis And Senescence Of Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus

Abnormal Expression of a Novel Apoptosis-Promoting Molecule TFAR19(PDCD5) in the Bone Marrow Cells from Adult Chronic Myeloid Leukemia

Detection of plasma soluble Fas in patients with multiple myeloma

Apoptosis of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythem atosus

[Research Progress on Gene Expression Abnormality of Hematopoietic Stem/Progenitor Cells in Myelodysplastic Syndromes].

Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes.

The Effects of Dexamethason on Apoptosis and Expressions of Fas,FasL in Peripheral Blood Lymphocytes from Patients with Systemic Lupus Erythematosus

Gene Expression of Fas，soluble Fas and Fas-ligand in Thyroid Tissues and Thyrocytes from Patients with Graves’disease

Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation

The correlation between quantitative expression of Fas receptor molecules on CD3+ T lymphocyte and disease activity of systemic lupus erythematosus

Mesenchymal-stem-cell-induced Immunoregulation Involves FAS-ligand-/FAS-mediated T Cell Apoptosis.